Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL
Condition(s):Natural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeLast Updated:September 14, 2021Unknown status
Hide Studies Not Open or Pending
Condition(s):Natural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeLast Updated:September 14, 2021Unknown status
Condition(s):Lymphoma, Extranodal NK-T-CellLast Updated:May 9, 2018Terminated
Condition(s):Acute Lymphoblastic Leukemia; Adult B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic LeukemiaLast Updated:April 27, 2021Completed
Condition(s):Acute Lymphoblastic Leukemia; Lymphoblastic LymphomaLast Updated:November 3, 2023Active, not recruiting
Condition(s):Treatment RefusalLast Updated:May 9, 2018Terminated
Condition(s):Acute Lymphoblastic LeukemiaLast Updated:December 3, 2013Withdrawn
Condition(s):Treatment RefusalLast Updated:June 18, 2023Recruiting
Condition(s):Acute Lymphoblastic LeukemiaLast Updated:May 22, 2014Completed
Condition(s):Acute Lymphoblastic LeukemiaLast Updated:February 19, 2019Recruiting
Condition(s):Acute Lymphoblastic Leukemia; Adult B Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic LeukemiaLast Updated:April 27, 2021Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.